Kimera Labs Receives FDA Phase I/IIa IND Clearance For Its MSC Exosomes Human Study

Kimera Labs has received FDA Phase I/IIa IND approval to study the safety and effects of mesenchymal stem cell (MSC)-derived exosomes in humans. This marks a major milestone in regenerative medicine, as exosomes are known for their ability to reduce inflammation, promote tissue repair, and support cellular communication. The study will assess their potential in treating conditions linked to inflammation and immune dysfunction. FDA approval of this study is a promising step toward further validating the therapeutic benefits of exosomes

Read the full article from Kimera Labs here.